Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 8/20 | 0.77 |
| ▸ | CES2 | O00748 | 7/20 | 0.77 |
| ▸ | GAPDH | P04406 | 4/20 | 0.75 |
| ▸ | IDO1 | P14902 | 2/20 | 0.54 |
| ▸ | CDC25A | P30304 | 2/20 | 0.54 |
| ▸ | CDC25B | P30305 | 2/20 | 0.54 |
| ▸ | P4HB | P07237 | 1/20 | 0.47 |
| ▸ | NSD2 | O96028 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.45 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | S100A4 | P26447 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GSR | P00390 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17594909 | 0.91 | GAPDH (0.89) | CES1CES2GAPDHIDO1CDC25A | |
| SCHEMBL4468407 | 0.86 | GAPDH (1.00) | CES1CES2GAPDHIDO1CDC25A | |
| SCHEMBL9713675 | 0.85 | CES2 (0.60) | CES1CES2GAPDHIDO1CDC25A | |
| SCHEMBL28916510 | 0.83 | GAPDH (0.75) | CES1CES2GAPDHIDO1CDC25A | |
| SCHEMBL9628251 | 0.83 | CES1 (0.77) | CES1CES2GAPDHIDO1CDC25A | |
| SCHEMBL29647693 | 0.83 | CES1 (0.77) | CES1CES2GAPDHIDO1CDC25A | |
| SCHEMBL9849815 | 0.83 | CES2 (0.77) | CES1CES2GAPDHIDO1CDC25A | |
| SCHEMBL17594484 | 0.83 | GAPDH (0.75) | CES1CES2GAPDHIDO1CDC25A | |
| SCHEMBL9713769 | 0.83 | GAPDH (0.69) | CES1CES2GAPDHIDO1CDC25A | |
| SCHEMBL19420523 | 0.80 | GAPDH (0.69) | CES1CES2GAPDHIDO1CDC25A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577315-B2 | Compositions and methods for treatment of prostate carcinoma | PELLFICURE PHARMACEUTICALS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-10577315-B2 | Compositions and methods for treatment of prostate carcinoma | PELLFICURE PHARMACEUTICALS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190169122-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS | 2019-06-06 | — | — | US | disclosed |
| US-20190169122-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS | 2019-06-06 | — | — | US | disclosed |
| US-10093620-B2 | Compositions and methods for treatment of prostate carcinoma | PELLFICURE PHARMACEUTICALS, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20170283374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170283374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170283374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS, INC. | 2017-10-05 | — | — | US | disclosed |
| EP-3191087-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | Pellficure Pharmaceuticals, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016040896-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| US-5155132-A | Nonsteroidal antiinflammatory agents; treating psoriasis | SYNTEX (U.S.A.) INC. (US) | 1992-10-13 | — | — | US | disclosed |
| US-5134161-A | Enzyme inhibitors for skin disorders, antiinflammatory agents | SYNTEX (U.S.A.) INC. (US) | 1992-07-28 | — | — | US | disclosed |
| US-5089657-A | Topical antiinflammatory agents | SYNTEX (U.S.A.) INC. (US) | 1992-02-18 | — | — | US | disclosed |
| US-4786652-A | TOPICAL ADMINISTRATION | SYNTEX (U.S.A.) INC. (US) | 1988-11-22 | — | — | US | disclosed |
| EP-0282056-A2 | Naphthalene anti-psoriatic agents | SYNTEX (U.S.A.) INC. (US) | 1988-09-14 | — | — | EP | disclosed |
| EP-0282006-A1 | Naphtalene anti-psoriatic agents | SYNTEX (U.S.A.) INC. (US) | 1988-09-14 | — | — | EP | disclosed |
| US-4758587-A | Naphthalene anti-psoriatic agents | SYNTEX (U.S.A.) INC. (US) | 1988-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10093620-B2 | Compositions and methods for treatment of prostate carcinoma | KLK3, ACP3, NR5A1 | CES1 928/4885CES2 2901/4885GAPDH 1168/4885 |
| US-20190169122-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | KLK3, ACP3, NR5A1 | CES1 928/4885CES2 2901/4885GAPDH 1168/4885 |
| US-20170283374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | KLK3, ACP3, NR5A1 | CES1 928/4885CES2 2901/4885GAPDH 1168/4885 |
| US-10577315-B2 | Compositions and methods for treatment of prostate carcinoma | KLK3, ACP3, NR5A1 | CES1 928/4885CES2 2901/4885GAPDH 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.